RxDoctor Payments Data

Michael Mathier

Cardiology · Pittsburgh, PANPI 1366417099

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.7% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Irhythm Technologies, Inc. at 36.0% of the total.

$59in general payments, 2019–2025

Across 4 payments — averaging $14.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Irhythm Technologies, Inc.$21
  • United Therapeutics Corporation$20
  • Merck$17
$127,142in research payments, 2019–2025

Across 25 payments — averaging $5085.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Actelion Pharmaceuticals, Ltd$78K
  • Merck$30K
  • United Therapeutics Corporation$19K

What the payments were for

  • Food & beverage$5696%
  • Education$34%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$59 in reported general payments places this provider in the 80th percentile of 43 cardiology providers in Pennsylvania.

See all cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$38,105
Medicare patients
181
Services billed
414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag93$1,986,568
WinrevairSotatercept-Csrk52$879,583
AdempasRiociguat60$834,928
Ambrisentan241$685,548
OpsumitMacitentan48$574,326
Orenitram ErTreprostinil Diolamine41$477,914
Tyvaso DpiTreprostinil17$398,590
EntrestoSacubitril/Valsartan208$302,379
Tadalafil272$301,687
JardianceEmpagliflozin221$294,375
LetairisAmbrisentan20$256,227
EliquisApixaban141$151,665
Sildenafil Citrate111$46,435
FarxigaDapagliflozin Propanediol45$44,807
XareltoRivaroxaban26$25,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckWinrevair$17$879,58352 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 43 cardiology providers in Pennsylvania.

Other cardiology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →